Cediranib

Drug Profile

Cediranib

Alternative Names: AZD-2171; Cediranib-maleate; Recentin; Zemfirza

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cancer Research UK; National Cancer Institute (Canada); National Cancer Institute (USA); University Health Network; University of Oxford
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Prostate cancer; Solid tumours
  • Discontinued Acute myeloid leukaemia; Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 25 Jan 2017 Phase-II clinical trials in Ovarian cancer (In adolescents, In adults, Combination Therapy, Second-line therapy or greater) in United Kingdom (PO) (EudraCT2016-000559-28)
  • 01 Jan 2017 AstraZeneca initiates the phase IIb CONCERTO trial for Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT02889900)
  • 31 Dec 2016 The Medical Research Council completes the phase II/III ICON6 trial in Ovarian cancer in Australia, Canada, New Zealand, Spain and United Kingdom (NCT00532194; ISRCTN68510403)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top